



Adherium®

AusBiotech Presentation

26 October 2016



INVESTMENT HIGHLIGHTS

Adherium provides valuable exposure to the rapidly growing digital health sector

- Commercialisation stage digital health company with a **clear path to profitability**
- Valuable intellectual property portfolio, with a 15 year investment in one of the **world's largest databases of respiratory medication data**
- Exciting opportunity to leverage proprietary Big Data into new healthcare applications, **positioning Adherium for scalable growth**
- Focus on growing market share via **existing AstraZeneca agreement and accessing new provider and payor markets**
- Large unmet market opportunity of **approximately US\$50 billion** across respiratory smart inhalers, other chronic diseases and global healthcare Big Data
- Significant Founder and Board ownership aligns incentives with **global institutional ownership**
- Strong balance sheet with **cash of A\$31.8 million to fund exciting growth opportunities**
- De-risked investment proposition – revenue-stage with **proprietary technology already developed and cleared for market**



POSITIONING ADHERIUM FOR COMMERCIALISATION

Adherium is now well positioned for rapid commercialisation and growth

Future milestones



DISCLAIMER AND FORWARD LOOKING STATEMENTS

The following material is of a general nature and has only been prepared as a presentation aid. This presentation does NOT contain all of the information that may be required for evaluating Adherium Limited ACN 605 352 510 (**Adherium**®), its assets, prospects or potential opportunities.

This presentation may contain budget information, forecasts and forward looking statements in respect of which there is NO guarantee of future performance and which of themselves involve significant risks (both known and unknown). Actual results and future outcomes will in all likelihood differ from those outlined herein. Forward-looking statements are statements that are not historical facts. Words such as “expect(s)”, “feel(s)”, “believe(s)”, “will”, “may”, “anticipate(s)” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding future results, regulatory approvals, production targets, sales, staffing levels etc. All of such statements are subject to risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.

These risks and uncertainties include, but are not limited to: (i) the possible delays in and the outcome of product development, (ii) risks relating to possible partnering or other like arrangements, (iii) the potential for delays in regulatory approvals, (iv) the unknown uptake and market penetration of any potential commercial products and (vi) other risks and uncertainties related to the Company’s prospects, assets / products and business strategy. This is particularly the case with companies such as Adherium which operate in the field of developing and commercializing devices. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events. Additionally there are a number of factors, both specific to Adherium and of a general nature, which may affect the future performance of Adherium. There is no guarantee that Adherium will achieve its stated objectives/milestones, that any of its forecasts will be met or that forward looking statements will be realized. Neither Adherium nor any other entity or person in or associated with the Adherium group of companies guarantees any return (whether capital or income) or generally the performance of Adherium or the price at which its securities may trade. Any investment in Adherium is subject to investment risks including the possibility of loss of capital invested and no return of income or payment of any dividends.

This presentation is not for general distribution or third party reliance or use. While it has been prepared from sources Adherium believe to be reliable, Adherium cannot guarantee its accuracy or completeness and, other than as required by law, Adherium undertakes NO obligation to advise of changes or updates to any such materials. These materials do NOT take into account any specific objectives, financial situation or needs of potential recipient/user. In addition, the past performance of Adherium cannot be assumed as indicative of the future performance of the Company.

For these and other reasons, before undertaking any evaluation of Adherium, its assets, prospects or opportunities you are strongly recommended to obtain your own up to date independent legal, financial and commercial advice – those acting without such advice do so at their own risk. Except as otherwise expressly stated in this presentation, Adherium has not authorized any person to give any information or make any representation which is not contained in this presentation. Any such information or representation not contained in this presentation must not be relied upon as having been authorized by, or on behalf of, Adherium.